SPG20 siRNA (Human)

siRNA to inhibit SPG20 expression using RNA interference
Supplier Cohesion Biosciences
Product # CRH8005
Pricing 15 nmol USD $340.0, 30 nmol USD $510.0
Source Synthetic
Reactivity H
Applications RNAi
Delivery Time Ship in 1 week
Specificity SPG20 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Form Lyophilized powder
Gene Symbol SPG20
Alternative Names KIAA0610; TAHCCP1; Spartin; Spastic paraplegia 20 protein; Trans-activated by hepatitis C virus core protein 1
Entrez Gene (Human) 23111.0
SwissProt (Human) Q8N0X7
Purity > 97%
Quality Control Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components We offers pre-designed sets of 3 different target-specific siRNA oligo duplexes of human SPG20 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Storage/Stability Shipped at 4 °C. Store at -20 °C for one year.
Datasheet http://www.cohesionbio.com/download/CRH8005.pdf
Feedback